JNJ-54861911, 50 mg

DRUG2 trials

Sponsors

Janssen Research & Development, LLC, Janssen Pharmaceutical K.K.

Conditions

Alzheimer's Disease

Phase 1

Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia

CompletedNCT02360657

Janssen Pharmaceutical K.K.Alzheimer's Disease

Start: 2015-02-16End: 2015-09-08Updated: 2019-02-04

Phase 2

A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

CompletedNCT02260674

Janssen Research & Development, LLCAlzheimer's Disease

Start: 2014-11-30End: 2016-06-30Updated: 2025-04-29

Related Papers

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.

2020-05-1480 citations

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

Alzheimer s Research & Therapy2018-08-22106 citations